<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACREM</journal-id><journal-title-group><journal-title>Asian Case Reports in Emergency Medicine</journal-title></journal-title-group><issn pub-type="epub">2328-0409</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACREM.2021.92004</article-id><article-id pub-id-type="publisher-id">ACREM-42369</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACREM20210200000_75463248.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  SCN2A基因突变相关的癫痫研究进展
   Research Advances in Epilepsy Related to SCN2A Gene Mutation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>潇颖</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>越</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆医科大学附属儿童医院神经内科，重庆；国家儿童健康与疾病临床医学研究中心，重庆；儿童发育疾病研究教育部重点实验室，重庆；儿童发育重大疾病国家国际科技合作基地，重庆；儿科学重庆市重点实验室，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>23</day><month>03</month><year>2021</year></pub-date><volume>09</volume><issue>02</issue><fpage>20</fpage><lpage>24</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   SCN2A (Sodium voltage-gated channel alpha subunit 2)基因编码的神经元电压门控钠通道Nav1.2是中枢神经系统表达的四个钠通道类似物之一，在大脑中分布广泛，参与一系列神经元动作电位的启动和传导。SCN2A基因突变所致的癫痫表型谱广，其基因突变类型和临床表型之间有很强的相关性，既可表现为良性预后的癫痫，也可表现为癫痫性脑病。SCN2A基因突变可为遗传性突变或新生突变，且突变类型多样，其中以错义突变最常见。该文就近年来SCN2A基因突变相关的癫痫研究进展进行阐述，总结其临床特征及遗传学特点，为治疗提供新思路。 The neuronal voltage-gated sodium channel Nav1.2 is encoded by SCN2A gene. And it is one of the four sodium channel analogues which expressed in the central nervous system. Nav1.2 is widely distributed in the brain and participates in the initiation and conduction of a series of neuronal action potentials. The epilepsy phenotype caused by SCN2A gene mutations has a wide spectrum, and there is a strong correlation between types of gene mutations and clinical phenotype. And the phenotype can be manifested as epilepsy with benign prognosis or epileptic encephalopathy. The SCN2A gene mutations can be hereditary mutations or de novo mutations, and there are various types of mutations, among which missense mutations are the most common. This article describes the research advance of SCN2A gene mutation related-epilepsy in recent years, summarizes its clinical and genetic characteristics, and provides new ideas for treatment. 
  
 
</p></abstract><kwd-group><kwd>SCN2A基因，癫痫，遗传,  SCN2A Gene</kwd><kwd> Epilepsy</kwd><kwd> Heredity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>SCN2A (Sodium voltage-gated channel alpha subunit 2)基因编码的神经元电压门控钠通道Nav1.2是中枢神经系统表达的四个钠通道类似物之一，在大脑中分布广泛，参与一系列神经元动作电位的启动和传导。SCN2A基因突变所致的癫痫表型谱广，其基因突变类型和临床表型之间有很强的相关性，既可表现为良性预后的癫痫，也可表现为癫痫性脑病。SCN2A基因突变可为遗传性突变或新生突变，且突变类型多样，其中以错义突变最常见。该文就近年来SCN2A基因突变相关的癫痫研究进展进行阐述，总结其临床特征及遗传学特点，为治疗提供新思路。</p></sec><sec id="s2"><title>关键词</title><p>SCN2A基因，癫痫，遗传</p></sec><sec id="s3"><title>Research Advances in Epilepsy Related to SCN2A Gene Mutation</title><p>Xiaoying Wang<sup>1,2,3,4,5</sup>, Yue Hu<sup>1,2,3,4,5*</sup></p><p><sup>1</sup>Department of Neurology, Children’s Hospital Affiliated to Chongqing Medical University, Chongqing</p><p><sup>2</sup>National Clinical Medical Research Center for Child Health and Disease, Chongqing</p><p><sup>3</sup>Key Laboratory of Child Developmental Disease Research of Ministry of Education, Chongqing</p><p><sup>4</sup>National International Science and Technology Cooperation Base for Major Childhood Developmental Diseases, Chongqing</p><p><sup>5</sup>Chongqing Key Laboratory of Pediatrics, Chongqing</p><p><img src="//html.hanspub.org/file/3-2440084x5_hanspub.png" /></p><p>Received: Mar. 18<sup>th</sup>, 2021; accepted: May 12<sup>th</sup>, 2021; published: May 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-2440084x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The neuronal voltage-gated sodium channel Nav1.2 is encoded by SCN2A gene. And it is one of the four sodium channel analogues which expressed in the central nervous system. Nav1.2 is widely distributed in the brain and participates in the initiation and conduction of a series of neuronal action potentials. The epilepsy phenotype caused by SCN2A gene mutations has a wide spectrum, and there is a strong correlation between types of gene mutations and clinical phenotype. And the phenotype can be manifested as epilepsy with benign prognosis or epileptic encephalopathy. The SCN2A gene mutations can be hereditary mutations or de novo mutations, and there are various types of mutations, among which missense mutations are the most common. This article describes the research advance of SCN2A gene mutation related-epilepsy in recent years, summarizes its clinical and genetic characteristics, and provides new ideas for treatment.</p><p>Keywords:SCN2A Gene, Epilepsy, Heredity</p><disp-formula id="hanspub.42369-formula36"><graphic xlink:href="//html.hanspub.org/file/3-2440084x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-2440084x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-2440084x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>癫痫作为神经系统最常见的疾病之一，世界卫生组织的调查数据显示，世界范围内的癫痫患病率为0.4%~0.7%，且癫痫在儿童中的发病率高于成人 [<xref ref-type="bibr" rid="hanspub.42369-ref1">1</xref>]，其反复发作可导致运动及感觉障碍、认知障碍、精神异常或者自主神经系统紊乱，而离子通道基因在癫痫的发病中起到了非常重要的作用。编码钠离子通道的SCN2A基因位于染色体2q24.3，该基因突变所引起的癫痫表型谱广，包括轻度的癫痫综合征、癫痫性脑病和严重的发育障碍。SCN2A基因可以常染色体显性遗传，其突变类型包括新生突变和遗传性突变，基因突变的位点不同，患儿的临床症状及预后也因此不同。近些年在癫痫的发作机制方面取得的研究进展对于癫痫治疗有很大的帮助，研究癫痫的发作机制以及基因突变类型和临床表型之间的相关性，对于癫痫治疗有极大帮助。</p></sec><sec id="s6"><title>2. SCN2A基因的结构和功能</title><sec id="s6_1"><title>2.1. SCN2A基因的结构</title><p>SCN2A基因位于人类2号染色体(2q24.3)上，包含26个外显子，编码2005个氨基酸，编码产物NaV1.2蛋白是中枢神经系统表达的四个钠通道类似物之一，与另外三个钠通道类似物Nav1.1 (SCN1A)、Nav1.3 (SCN3A)、Nav1.6 (SCN8A)一起参与一系列神经元动作电位的启动和传导 [<xref ref-type="bibr" rid="hanspub.42369-ref2">2</xref>]。</p></sec><sec id="s6_2"><title>2.2. Nav1.2的结构</title><p>Nav1.2是由四个高度相似的结构域(I, II, III, IV)组成的假四聚体蛋白，每个结构域包含６个跨膜片段S1~S6，其中S1~S4形成电压敏感结构域，S4构成电压传感器，对膜的胞内侧和胞外侧的电荷差异很敏感，S5~S6形成孔环和DEKA选择性过滤器 [<xref ref-type="bibr" rid="hanspub.42369-ref3">3</xref>]。Nav1.2在人类的中枢神经系统中分布很广泛，主要分布在兴奋性神经元轴突起始段、未髓鞘化轴突部位，且在皮质、海马、纹状体、中脑中呈高表达，与动作电位的产生有着密切关系。在皮质结构中，Nav1.2和Nav1.6主要在兴奋性谷氨酸神经元中共表达，而在小脑皮层中，主要在兴奋性颗粒细胞的无髓轴突中表达 [<xref ref-type="bibr" rid="hanspub.42369-ref4">4</xref>]。</p></sec><sec id="s6_3"><title>2.3. SCN2A基因的功能</title><p>SCN2A基因编码的电压门控钠离子通道Nav1.2，多表达于发育中的脑及朗飞节和轴突起始段，主要参与动作电位初始的钠离子快速流入以及动作电位的传播，在兴奋性神经元动作电位的形成及传播中及神经元塑形过程中起重要作用。因此，SCN2A基因突变主要影响胎儿期的神经发育，但也有可能引起迟发性神经系统疾病。</p><p>SCN2A基因的表达开始于妊娠早期，表达高峰在出生前后，在神经元兴奋性中起主导作用，对神经元动作电位的启动和传播至关重要 [<xref ref-type="bibr" rid="hanspub.42369-ref5">5</xref>]。高峰表达过后Nav1.2的功能在很大程度上被SCN8A编码的Nav1.6取代，一旦动作电位由Nav1.6启动，Nav1.2将有助于动作电位反向传播到躯体树突，这些反向传播的动作电位可以影响许多功能，如：活性依赖的基因转录、突触整合和突触可塑性 [<xref ref-type="bibr" rid="hanspub.42369-ref6">6</xref>]。</p><p>SCN2A基因对维持正常中枢神经系统的功能非常重要，编码Nav1.2的SCN2A基因发生突变，主要引起神经元细胞膜上钠离子通道的结构及功能异常，造成神经元异常放电。通常情况下，钠离子通道处于备用状态、激活状态和失活状态三种功能状态之一，往往需经过激活、失活、失活恢复三个步骤才能进入后续激活状态，钠离子通道所在的功能状态，决定着其是否具有发生动作电位的活性，编码钠离子通道的基因发生错义突变则可影响上述三个步骤 [<xref ref-type="bibr" rid="hanspub.42369-ref2">2</xref>]。由SCN2A基因的错义突变引起的氨基酸序列的微小变化可导致钠离子通道的功能改变，包括钠离子通道功能增强、钠离子通道功能减弱或两者兼具。错义突变导致的蛋白质改变几乎全部位于离子通道功能的重要区域，位于发育高度保守区域的氨基酸与通道功能相关，因此在发生错义突变后会导致功能改变 [<xref ref-type="bibr" rid="hanspub.42369-ref7">7</xref>]。</p></sec></sec><sec id="s7"><title>3. SCN2A基因的遗传学特征</title><p>SCN2A基因以常染色体显性方式遗传，近年来已报道多种SCN2A基因突变类型，包括错义突变、框内碱基缺失或插入突变、无义突变、移码突变、剪切位点突变，其中以错义突变最为常见 [<xref ref-type="bibr" rid="hanspub.42369-ref8">8</xref>]。另外，SCN2A基因突变可分为遗传性突变或新生突变，文献报道：遗传性突变多见于预后良好的良性家族性新生儿癫痫、良性家族性新生儿–婴儿癫痫、良性家族性婴儿癫痫和全面性癫痫伴热性惊厥附加症等 [<xref ref-type="bibr" rid="hanspub.42369-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.42369-ref10">10</xref>]，而新生突变多见于预后不良的癫痫性脑病，如：大田原综合征 [<xref ref-type="bibr" rid="hanspub.42369-ref11">11</xref>]、婴儿癫痫伴游走性局灶性发作 [<xref ref-type="bibr" rid="hanspub.42369-ref12">12</xref>]、婴儿痉挛症 [<xref ref-type="bibr" rid="hanspub.42369-ref13">13</xref>]、Lennox-Gastaut综合征和不能分类的早发性癫痫性脑病 [<xref ref-type="bibr" rid="hanspub.42369-ref14">14</xref>] 等。</p></sec><sec id="s8"><title>4. SCN2A基因突变所致癫痫类型</title><p>SCN2A基因与神经系统发育密切相关，SCN2A基因突变可导致癫痫、智力障碍、精神分裂症、孤独症谱系障碍性疾病以及其他神经系统疾病。SCN2A基因突变具有表型异质性，不同突变位点所造成的癫痫表型各异，该基因是多种癫痫综合征的致病基因，与其相关的癫痫表型谱很广 [<xref ref-type="bibr" rid="hanspub.42369-ref15">15</xref>]，神经发育障碍性疾病的遗传学研究发现SCN2A基因主要与以下三种疾病相关：</p><sec id="s8_1"><title>4.1. 良性家族性新生儿–婴儿癫痫(Benign Familial Neonate-Infant Epilepsy, BFNIE)</title><p>BFNIE是一种常染色体显性遗传性癫痫，是首次报道的SCN2A基因突变相关癫痫表型，其变异有可能是新生突变，也有可能是遗传性突变。癫痫发作年龄从生后第一天至23个月不等，大约一半的患儿在新生儿期发病，主要发作类型为无热性局灶性发作，继发全面性发作，发作间期脑电图多呈局灶性或多灶性棘波，但部分病例的脑电图正常 [<xref ref-type="bibr" rid="hanspub.42369-ref13">13</xref>]，一般在2岁左右好转，少部分患者在儿童期出现其他类型癫痫，但总体预后良好，没有明显神经系统后遗症。报道显示，无论是否予以抗癫痫治疗，绝大多数患儿均在1岁以内缓解，可见其病程存在一定自限性。</p></sec><sec id="s8_2"><title>4.2. 癫痫性脑病</title><p>这类疾病根据发病年龄可分为两个年龄组，小于和大于3月龄，这一分组对于预测药物治疗反应有所帮助，对于长期预后及预测其他系统共患病意义不大 [<xref ref-type="bibr" rid="hanspub.42369-ref12">12</xref>]。</p><sec id="s8_2_1"><title>4.2.1. 发病年龄小于3月龄</title><p>癫痫在出生后3月内出现，多于新生儿期发病，癫痫通常表现为局灶性、强直性、强直性阵挛性发作和痉挛，部分可归类为癫痫综合征，最常见的是大田原综合征(Otawara Syndrome, OS)和婴儿癫痫伴游走性局灶性发作(Epilepsy of infancy with migrating focal seizures, EIMFS)。这类突变通常为钠通道功能增强型突变(Gain-of-function, GOF)，钠通道阻滞剂治疗有效，尤其是苯妥因，60%患儿的癫痫可得到控制，其中2/3在1岁内缓解，1/3在儿童期缓解 [<xref ref-type="bibr" rid="hanspub.42369-ref16">16</xref>]。</p></sec><sec id="s8_2_2"><title>4.2.2. 发病年龄大于3月龄</title><p>癫痫通常在出生后3月出现，多于4岁之前发作，这类疾病包括婴儿痉挛症、Lennox-Gastaut综合征、肌阵挛性强直性癫痫、Dravet样综合征和不能分类的早发性癫痫性脑病等。这类突变包括钠通道功能缺失型突变(Loss-of-function, LOF)或兼有GOF和LOF的错义突变。钠通道阻滞剂对这类癫痫无效，甚至可能导致癫痫发作加重，非钠通道阻滞剂可能有效。这些癫痫综合征往往发作频繁、药物难以控制，报道仅有35%可达到缓解 [<xref ref-type="bibr" rid="hanspub.42369-ref17">17</xref>]。</p><p>这两组癫痫性脑病患儿均报道有智力障碍，在晚发型癫痫性脑病中，在癫痫发作前认知水平可从正常到严重迟缓。在这些表型中都可存在许多合并症 [<xref ref-type="bibr" rid="hanspub.42369-ref18">18</xref>]，如孤独症谱系障碍、肌张力减退、运动障碍、小脑畸形、脑和/或小脑萎缩、胼胝体发育不良及髓鞘化不良等。</p></sec></sec><sec id="s8_3"><title>4.3. 孤独症谱系障碍/智力障碍</title><p>这类疾病通常在出生后6月内发育正常，其后出现中度的运动发育迟缓和严重的语言发育迟缓。这类患者一般喜欢与亲近的人进行身体接触，拒绝与他人或新奇的物体接触，倾向于重复动作，很少主动发起社交活动及眼神接触，对他人的社交暗示反应迟钝。约有1/3病例出现癫痫发作，通常在18个月至4岁之间，这类突变通常为钠通道功能缺失型突变，对非钠通道阻滞剂治疗有反应 [<xref ref-type="bibr" rid="hanspub.42369-ref19">19</xref>]，癫痫发作通常与发育延迟有关，特别是发作严重时会出现发育倒退。</p><p>SCN2A基因突变相关患者，大部分予以钠离子通道阻滞剂，如奥卡西平、卡马西平、苯妥英钠、拉莫三嗪等，可有效控制癫痫发作，但有部分患儿无效甚至加重。其原因可能是与发病早晚、对钠通道阻滞剂反应与SCN2A的不同突变功能特性相关。早期发病的相关突变可导致钠通道活性增加，予以钠通道阻滞剂治疗后效果良好，而晚发型相关突变则多致钠通道功能减低甚至丧失，故予以钠通道阻滞剂不仅无效甚至可能导致癫痫发作加重 [<xref ref-type="bibr" rid="hanspub.42369-ref14">14</xref>]。</p></sec></sec><sec id="s9"><title>5. 小结</title><p>近年来临床研究对于SCN2A基因突变类型与临床表型之间的联系逐渐明朗化。SCN2A基因突类型多样，且介导的癫痫表型谱广，SCN2A基因突变导致Nav1.2通道功能状态改变是癫痫发作的重要因素，了解钠离子通道如何影响神经元发育和成熟，恢复Nav1.2通道功能正常化是有效干预及治疗的关键之处。随着未来基因技术的发作，癫痫的遗传学研究亦可进一步发展，从而研发出更多疗效显著的抗癫痫药物来提高临床治疗效果。</p></sec><sec id="s10"><title>文章引用</title><p>王潇颖,胡 越. SCN2A基因突变相关的癫痫研究进展 Research Advances in Epilepsy Related to SCN2A Gene Mutation[J]. 亚洲急诊医学病例研究, 2021, 09(02): 20-24. https://doi.org/10.12677/ACREM.2021.92004</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42369-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Maloney, E.M., Chaila, E., O’Reilly, I.J., et al. (2020) The Incidence of First Seizures, Epilepsy and Seizure Mimics in a Geographically Defined Area. Neurology, 95, e576-e590.</mixed-citation></ref><ref id="hanspub.42369-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hedrich, U., Lauxmann, S. and Lerche, H. (2019) SCN2A Channelopathies: Mechanisms and Models. Epilepsia, 60, S68-S76. &lt;br&gt;https://doi.org/10.1111/epi.14731</mixed-citation></ref><ref id="hanspub.42369-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mason, E.R., Wu, F., et al. (2019) Resurgent and Gating Pore Currents In-duced by De Novo SCN2A Epilepsy Mutations. eNeuro, 6, ENEURO.0141-19. &lt;br&gt;https://doi.org/10.1523/ENEURO.0141-19.2019</mixed-citation></ref><ref id="hanspub.42369-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">康庆云, 廖红梅, 陈玫, 等. 5例SCN2A基因突变相关癫痫性脑病患儿的临床特征及基因突变分析[J]. 癫痫与神经电生理学杂志, 2020, 29(5): 257-261.</mixed-citation></ref><ref id="hanspub.42369-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Reynolds, C., King, M.D. and Gorman, K.M. (2020) The Phenotypic Spectrum of SCN2A-Related Epilepsy. European Journal of Paediatric Neurology, 24, 117-122. &lt;br&gt;https://doi.org/10.1016/j.ejpn.2019.12.016</mixed-citation></ref><ref id="hanspub.42369-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Adney, S.K., Millichap, J.J., DeKeyser, J.M., et al. (2020) Functional and Pharmacological Evaluation of a Novel SCN2A Variant Linked to Ear-ly-Onset Epilepsy. Annals of Clinical and Translational Neurology, 7, 1488-1501.  
&lt;br&gt;https://doi.org/10.1002/acn3.51105</mixed-citation></ref><ref id="hanspub.42369-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Begemann, A., Acuña, M.A., Zweier, M., et al. (2019) Further Corrobora-tion of Distinct Functional Features in SCN2A Variants Causing Intellectual Disability or Epileptic Phenotypes. Molecu-lar Medicine, 25, Article No. 6.  
&lt;br&gt;https://doi.org/10.1186/s10020-019-0073-6</mixed-citation></ref><ref id="hanspub.42369-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lauxmann, S., Verbeek, N.E., Liu, Y., et al. (2018) Relationship of Electrophysiological Dysfunction and Clinical Severity in SCN2A-Related Epilepsies. Human Mutation, 39, 1942-1956. &lt;br&gt;https://doi.org/10.1002/humu.23619</mixed-citation></ref><ref id="hanspub.42369-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sugawara, T., Tsurubuchi, Y., Agarwala, K.L., et al. (2001) A Missense Mutation of the Na+ Channel Alpha II Subunit Gene Na(v)1.2 in a Patient with Febrile and Afebrile Seizures Causes Channel Dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 98, 6384-6389. &lt;br&gt;https://doi.org/10.1073/pnas.111065098</mixed-citation></ref><ref id="hanspub.42369-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zara, F., Specchio, N., Striano, P., et al. (2013) Genetic Testing in Benign Familial Epilepsies of the First Year of Life: Clinical and Diagnostic Significance. Epilepsia, 54, 425-436. &lt;br&gt;https://doi.org/10.1111/epi.12089</mixed-citation></ref><ref id="hanspub.42369-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nakamura, K., Kato, M., Osaka, H., et al. (2013) Clinical Spec-trum of SCN2A Mutations Expanding to Ohtahara Syndrome. Neurology, 81, 992-998. &lt;br&gt;https://doi.org/10.1212/WNL.0b013e3182a43e57</mixed-citation></ref><ref id="hanspub.42369-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Howell, K.B., et al. (2015) SCN2A Encephalopathy a Major Cause of Epilepsy of Infancy with Migrating Focal Seizures. Neurology, 85, 958-966. &lt;br&gt;https://doi.org/10.1212/WNL.0000000000001926</mixed-citation></ref><ref id="hanspub.42369-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wolff, M., Brunklaus, A. and Zuberi, S.M. (2019) Pheno-typic Spectrum and Genetics of SCN2A-Related Disorders, Treatment Options, and Outcomes in Epilepsy and Beyond. Epilepsia, 60, S59-S67. &lt;br&gt;https://doi.org/10.1111/epi.14935</mixed-citation></ref><ref id="hanspub.42369-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wolff, M., Johannesen, K.M., Hedrich, U.B.S., et al. (2017) Genetic and Phenotypic Heterogeneity Suggest Therapeutic Implications in SCN2A-Related Disorders. Brain: A Journal of Neurology, 140, 1316-1336.  
&lt;br&gt;https://doi.org/10.1093/brain/awx054</mixed-citation></ref><ref id="hanspub.42369-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Su, D.J., Lu, J.F., Lin, L.J., et al. (2018) SCN2A Mutation in an Infant Presenting with Migrating Focal Seizures and Infantile Spasm Responsive to a Ketogenic Diet. Brain &amp; Development, 40, 724-727.  
&lt;br&gt;https://doi.org/10.1016/j.braindev.2018.03.005</mixed-citation></ref><ref id="hanspub.42369-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Melikishvili, G., Dulac, O. and Gataullina, S. (2020) Neonatal SCN2A Encephalopathy: A Peculiar Recognizable Electroclinical Sequence. Epilepsy &amp; Behavior, 111, Article ID: 107187. &lt;br&gt;https://doi.org/10.1016/j.yebeh.2020.107187</mixed-citation></ref><ref id="hanspub.42369-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kong, Y., Yan, K., Hu, L., et al. (2018) Association between SCN1A and SCN2A Mutations and Clinical/EEG Features in Chinese Patients from Epilepsy or Severe Sei-zures. Clinica Chimica Acta, 483, 14-19.  
&lt;br&gt;https://doi.org/10.1016/j.cca.2018.03.027</mixed-citation></ref><ref id="hanspub.42369-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, P., He, N., Zhang, J.W., et al. (2018) Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies. Genes, Brain and Behavior, 17, e12456. &lt;br&gt;https://doi.org/10.1111/gbb.12456</mixed-citation></ref><ref id="hanspub.42369-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Deborah, J.M. and Marc-Antoine, C. (2020) Neurodevelopmental Disor-ders—The History and Future of a Diagnostic Concept. Dialogues in Clinical Neuroscience, 22, 65-72. &lt;br&gt;https://doi.org/10.31887/DCNS.2020.22.1/macrocq</mixed-citation></ref></ref-list></back></article>